
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded nasal spray containing dihydroergotamine mesylate, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing dihydroergotamine are listed in spray, injection and powder forms.
This dose form is water-containing (aqueous). Under USP <795>, aqueous preparations carry shorter default beyond-use dates than nonaqueous ones, and a preservative in the base allows a longer date than no preservative. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Dihydroergotamine mesylate is an ergot alkaloid migraine medicine given by injection or into the nose that a pharmacy may compound when a prescriber orders it.
Dihydroergotamine (DHE) is a semisynthetic ergot alkaloid made by chemically modifying ergotamine, a compound from a fungus that grows on rye. It binds strongly to serotonin 5-HT1D receptors, an action thought to account for its effect in migraine, and also acts on other serotonin, adrenergic and dopamine receptors. Manufactured products include dihydroergotamine mesylate injection and the Brekiya autoinjector, indicated for acute treatment of migraine with or without aura and of cluster headache episodes (Brekiya in adults), and Trudhesa nasal spray, indicated for acute treatment of migraine in adults. Generic nasal sprays are also listed on DailyMed. The Trudhesa and Brekiya labels state they are not indicated to prevent migraine or for hemiplegic migraine, and the Trudhesa limitation reads hemiplegic or basilar migraine. A prescriber might order dihydroergotamine compounded in a strength or form that is not manufactured. Compounded preparations are not FDA-approved and require a prescription.
Dihydroergotamine labels carry a boxed warning: serious or life-threatening peripheral ischemia (loss of blood flow to the brain, hands or feet) has occurred when it was combined with strong CYP3A4 inhibitors such as ritonavir, clarithromycin, erythromycin, ketoconazole or itraconazole, so these combinations are contraindicated. Do not use it within 24 hours of a triptan or another ergot medicine, or if you have heart disease, uncontrolled high blood pressure, peripheral artery disease, severe liver or kidney disease, or an ergot allergy. Heart attack, stroke, vasospasm and, with prolonged daily use, fibrosis have been reported. Ask about grapefruit, and tell your prescriber if you smoke. It may cause preterm labor, so the label advises avoiding it in pregnancy. Do not breastfeed during treatment and for 3 days after the last dose (label and LactMed). Get emergency care for chest pain, numb or cold fingers or toes, or sudden weakness or trouble speaking, and talk to your prescriber or pharmacist about side effects.
Dihydroergotamine binds with high affinity to 5-HT1D receptors, the effect generally credited for its migraine activity, and also to 5-HT1A, 5-HT2A and 5-HT2C, alpha-adrenergic, and dopamine D2 and D3 receptors; it has oxytocic properties. A 2020 review describes greater alpha-adrenergic antagonism and less arterial vasoconstriction than ergotamine, absolute bioavailability of 100% by injection and about 40% intranasally, and low oral bioavailability from extensive first-pass metabolism. Protein binding is 93%. It is metabolized in the liver to an active metabolite, 8'-beta-hydroxy dihydroergotamine, and excreted mainly in bile; only 6% to 7% appears unchanged in urine after intramuscular dosing. Mean apparent half-life after Trudhesa is about 12 hours. Labeled indications: injection (ANDA) and Brekiya (NDA) for acute migraine and cluster headache; Trudhesa (NDA) for acute migraine in adults. The review describes repetitive intravenous DHE protocols for status migrainosus, medication overuse headache and refractory migraine, which are not FDA-approved indications. Dosing is per prescriber; labels advise against chronic daily use. Use moderate CYP3A4 inhibitors with caution. A cardiovascular evaluation is recommended before the first dose, with the first dose under supervision and an ECG in patients with coronary risk factors. Dihydroergotamine is not a controlled substance.
Wash your hands and blow your nose gently. Prime the pump if your label says to. Keep your head upright, close one nostril with a finger, insert the tip into the other nostril and breathe in slowly while pressing the pump the number of times on your label. Repeat in the other nostril if directed. Wipe the nozzle, recap, and wash your hands. Do not share the bottle.
Nasal sprays are aqueous. Under USP <795>, a preserved spray usually carries a beyond-use date of up to 35 days at room temperature or refrigerated, and an unpreserved one 14 days refrigerated. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Inhale intranasally